ArticleThe Prostate2013
Polymorphisms in CYP17 and CYP3A4 and prostate cancer in men of African descent.
Article in The Prostate, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 3 syntheses or guidelines pooled it, 36 citations in OpenAlex.
- Comparison of Response to Definitive Radiotherapy for Localized Prostate Cancer in Black and White Men: A Meta-analysis.JAMA network open · 2021Pooled it
- Pharmacogenetic research activity in Central America and the Caribbean: a systematic review.Pharmacogenomics · 2016Pooled it
- Association between the CYP3A4 and CYP3A5 polymorphisms and cancer risk: a meta-analysis and meta-regression.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Pooled it
- Association between CYP17A1 and HSD3B1 gene polymorphisms and testosterone levels in Nigerian prostate cancer patients.Scientific reports · 2025Article
- Racial disparities in prostate cancer in the UK and the USA: similarities, differences and steps forwards.Nature reviews. Urology · 2025Review
- Prostate Cancer: A Review of Genetics, Current Biomarkers and Personalised Treatments.Cancer reports (Hoboken, N.J.) · 2024Review
- Racial disparity in prostate cancer in the African American population with actionable ideas and novel immunotherapies.Cancer reports (Hoboken, N.J.) · 2021Review
- Article
- The Cancer Prevention Project of Philadelphia: preliminary findings examining diversity among the African diaspora.Ethnicity & health · 2021Article
- The Impact of African Ancestry on Prostate Cancer Disparities in the Era of Precision Medicine.Genes · 2020Review
- Association Between CYP17A1, CYB5A Polymorphisms and Efficacy of Abiraterone Acetate/Prednisone Treatment in Castration-Resistant Prostate Cancer Patients.Pharmacogenomics and personalized medicine · 2020Article
- Placing prostate cancer disparities within a psychosocial context: challenges and opportunities for future research.Cancer causes & control : CCC · 2019Review
- Evaluation of the contribution of demographics, access to health care, treatment, and tumor characteristics to racial differences in survival of advanced prostate cancer.Prostate cancer and prostatic diseases · 2019Article
- Role of Alternative Splicing in Prostate Cancer Aggressiveness and Drug Resistance in African Americans.Advances in experimental medicine and biology · 2019Review
- Prostate Cancer Genomics: Recent Advances and the Prevailing Underrepresentation from Racial and Ethnic Minorities.International journal of molecular sciences · 2018Review
- African-American Prostate Cancer Disparities.Current urology reports · 2017Review
- Molecular mechanisms involving prostate cancer racial disparity.American journal of clinical and experimental urology · 2017Review
- Serum androgens and prostate cancer risk: results from the placebo arm of the Prostate Cancer Prevention Trial.Cancer causes & control : CCC · 2016Article
- Prostate cancer in men of African origin.Nature reviews. Urology · 2016Review
- Polymorphisms of Estrogen Metabolism-Related Genes and Prostate Cancer Risk in Two Populations of African Ancestry.PloS one · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 12 institutions in 4 countries.
Funding
Abstract
backgroundA meta and pooled analysis of published and unpublished case-control studies was performed to evaluate the association of CYP17 (rs743572) and CYP3A4 (rs2740574) polymorphisms and prostate cancer (PCa) in men from the USA, Caribbean, and Africa.
methodsEight publications (seven studies) and two unpublished studies for CYP17 included 1,580 subjects (559 cases and 1,021 controls) and eleven publications and three unpublished studies for CYP3A4 included 3,400 subjects (1,429 cases and 1,971 controls).
resultsOverall, the CYP17 heterozygous and homozygous variants were not associated with PCa, but they confer a 60% increased risk of PCa in a sub-group analysis restricted to African-American men (T/C + C/C, OR: 1.6, 95% CI: 1.1-2.4). No associations were observed for CYP3A4, overall and in stratified analyses for African-Americans and Africans. The pooled analysis suggests that after adjusting for study, age, PSA, and family history of PCa, CYP17 was associated with PCa for men of African ancestry (Adjusted OR: 3.5, 95% CI: 1.2-10.0).
conclusionsOur findings suggest that genetic factors involved in the androgen pathway play a role in PCa risk among men of African ancestry.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.